Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.EBIOM.2015.09.007 | ||||
| Año | 2015 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Neisseria meningitidis is a leading bacterial cause of sepsis and meningitis globally with dynamic strain distribution over time. Beginning with an epidemic among Hajj pilgrims in 2000, serogroup W (W) sequence type (ST) 11 emerged as a leading cause of epidemic meningitis in the African 'meningitis belt' and endemic cases in South America, Europe, Middle East and China. Previous genotyping studies were unable to reliably discriminate sporadic W ST-11 strains in circulation since 1970 from the Hajj outbreak strain (Hajj clone). It is also unclear what proportion of more recent W ST-11 disease clusters are caused by direct descendants of the Hajj clone. Whole genome sequences of 270 meningococcal strains isolated from patients with invasive meningococcal disease globally from 1970 to 2013 were compared using whole genome phylogenetic and major antigen-encoding gene sequence analyses. We found that all W ST-11 strains were descendants of an ancestral strain that had undergone unique capsular switching events. The Hajj clone and its descendants were distinct from other W ST-11 strains in that they shared a common antigen gene profile and had undergone recombination involving virulence genes encoding factor H binding protein, nitric oxide reductase, and nitrite reductase. These data demonstrate that recent acquisition of a distinct antigen-encoding gene profile and variations in meningococcal virulence genes was associated with the emergence of the Hajj clone. Importantly, W ST-11 strains unrelated to the Hajj outbreak contribute a significant proportion of W ST-11 cases globally. This study helps illuminate genomic factors associated with meningococcal strain emergence and evolution. (C) 2015 The Authors. Published by Elsevier B.V.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Mustapha, Mustapha M. | Hombre |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh - Estados Unidos |
| 2 | Marsha, Jane W. | Mujer |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh - Estados Unidos |
| 2 | Marsh, Jane W. | - |
University of Pittsburgh - Estados Unidos
|
| 3 | Krauland, Mary G. | Mujer |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Graduate School of Public Health - Estados Unidos University of Pittsburgh - Estados Unidos |
| 4 | FERNANDEZ-ORDENES, JORGE OSVALDO | Hombre |
Publ Hlth Inst Chile - Chile
Instituto de Salud Pública de Chile - Chile |
| 5 | de Lemos, Ana Paula S. | Mujer |
Adolfo Lutz Inst - Brasil
Instituto Adolfo Lutz - Brasil |
| 6 | Hotopp, Julie C. Dunning | Mujer |
UNIV MARYLAND - Estados Unidos
|
| 6 | Dunning Hotopp, Julie C. | Mujer |
University of Maryland School of Medicine - Estados Unidos
UNIV MARYLAND - Estados Unidos |
| 7 | Wang, Xin | - |
Ctr Dis Control & Prevent - Estados Unidos
National Center for Immunization and Respiratory Diseases - Estados Unidos |
| 8 | Mayer, Leonard W. | Hombre |
Ctr Dis Control & Prevent - Estados Unidos
National Center for Immunization and Respiratory Diseases - Estados Unidos |
| 9 | Lawrence, Jeffrey G. | Hombre |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh - Estados Unidos |
| 10 | Hiller, N. Luisa | - |
Carnegie Mellon Univ - Estados Unidos
Carnegie Mellon University - Estados Unidos |
| 11 | Harrison, Lee H. | Hombre |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh - Estados Unidos |
| Fuente |
|---|
| National Institutes of Health |
| European Commission |
| Wellcome Trust |
| National Institute of Allergy and Infectious Diseases |
| U.S. Department of Health and Human Services |
| NIAID NIH HHS |
| University of Pittsburgh Department of Epidemiology |
| Agradecimiento |
|---|
| Dr. Harrison reports grants and personal fees from Sanofi Pasteur, personal fees from GSK, personal fees from Merck, personal fees from Novartis, personal fees from Pfizer, outside the submitted work; and all relationships with industry were terminated before I became a voting member of the Advisory Committee on Immunization Practices on July 1, 2012. Dr. Lemos reports travel grants and personal fees from Novartis, personal fees from Sanofi Pasteur, travel grants from GSK, outside the submitted work. Other co-authors have no interests to declare. |